Enjoying the archive? Get new posts in your inbox.
CV
+4
Aug 18, 2026
•
14 min read
It's Already on Every Panel. Nobody Reads It.
Remnant cholesterol costs nothing to calculate and predicts events when LDL no longer does. Its first real drug just proved it can prevent pancreatitis, and then failed to move plaque.
CV
+4
Aug 15, 2026
•
9 min read
One in Five Carry It. Nothing You Prescribe Touches It.
Lp(a) is the most common inherited cardiovascular risk factor in medicine — and the first outcomes trial that could give us a drug for it has gone quiet.
Coverage
+4
Aug 8, 2026
•
13 min read
Every First Claim Is Denied. That's the Design.
One month into the Medicare GLP-1 Bridge, the denial at the counter isn't a coverage decision — and CMS built no appeals process for the ones that are.
GLP1
+4
Aug 4, 2026
•
12 min read
Retatrutide Won Twice. The Heart Data Didn't.
TRIUMPH-2 and TRIUMPH-3 both hit — 20.8% in type 2 diabetes, 22.6% with established cardiovascular disease. Then there's the MACE table.
